Aclaris Therapeutics, Inc.·4

Feb 3, 4:46 PM ET

Ruffo Frank 4

4 · Aclaris Therapeutics, Inc. · Filed Feb 3, 2022

Insider Transaction Report

Form 4
Period: 2022-02-01
Ruffo Frank
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2022-02-01+3,875173,747 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-02-013,8750 total
    Common Stock (3,875 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F2]The shares underlying these restricted stock units vested on February 1, 2022.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION